Recent Finacing
Recent Raise
GeneVentiv develops GENV-HEM, an AAV8 vector expressing activated Factor V for single‑infusion treatment of hemophilia A and B, progressing from mouse efficacy toward large‑animal and IND studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at GeneVentiv Therapeutics.
